Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis
Authors:
Open Access
- 21 April 2022
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 82 (1) , 82-96
Abstract
No abstract availableKeywords
Funding Information
- European Association of Urology
This publication has 52 references indexed in Scilit:
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant StudyJournal of Clinical Oncology, 2014
- Adjuvant leuprolide with or without docetaxel in patients with high‐risk prostate cancer after radical prostatectomy (TAX‐3501)Cancer, 2013
- Automating network meta‐analysisResearch Synthesis Methods, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorialBMC Medical Research Methodology, 2010
- Long‐term follow‐up of 3‐month neoadjuvant hormone therapy before radical prostatectomy in a randomized trialBJU International, 2010
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- High-risk prostate cancer in the United States, 1990–2007World Journal of Urology, 2008
- Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancerSeminars in Oncology, 2001